Phase 4 N=30 Treatment

Phase 4 Study Evaluating the Safety of the Nasal Guide With Tyrvaya

Dry Eye · Keratoconjunctivitis Sicca

Bottom Line

View on ClinicalTrials.gov: NCT05918406 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

May 2025

Primary outcome: Primary: Number of Participants With Adverse Events — 30 Participants

Study Design & Population

Study type: Interventional
Phase: Phase 4
Interventions: Nasal Guide (Combination_product)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Oyster Point Pharma, Inc.
Primary completion: Aug 2023

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Participants With Adverse Events	30	—

Summary

The objective of this study is to determine the safety of the nasal guide when utilized to aid in the administration of Tyrvaya (varenicline solution 0.03mg) Nasal Spray

Eligibility Criteria

Inclusion Criteria

Be at least 18 years of age
Have provided verbal and written informed consent
Willing to comply with all study related visits and procedures

Exclusion Criteria

None

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05918406). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.